Enanta Pharmaceuticals Founded

Yat Sun Or, Ph.D. Joins Enanta Pharmaceuticals as Chief Scientific Officer

Jay R. Luly, Ph.D. Joins Enanta Pharmaceuticals as President and Chief Executive Officer

Enanta Pharmaceuticals Licenses EDP-420 for the Treatment of Community-Acquired Pneumonia to Shionogi

Enanta Pharmaceuticals and Chiron Announce Collaboration to Develop Hepatitis C Protease Inhibitors

Enanta Pharmaceuticals and Abbott Announce Agreement to Develop Protease Inhibitors for Hepatitis C Virus

Enanta’s Lead HCV Protease Inhibitor Compound ABT-450 Advances into Phase 3 Clinical Trial in a Triple Combination Treatment with Abbott’s NS5A Inhibitor

Enanta Pharmaceuticals Enters into Strategic Collaboration with Novartis to Advance Enanta’s NS5A Inhibitor Candidate for Hepatitis C Virus

Enanta Pharmaceuticals Launches Initial Public Offering

Enanta Pharmaceuticals and AbbVie Announce FDA Approves VIEKIRA PAK®, AbbVie’s Combination Drug for the Treatment of Chronic Genotype 1 Hepatitis C Virus

Enanta Pharmaceuticals and AbbVie Announce European Commission Grants Marketing Authorization for AbbVie’s VIEKIRAX™

Enanta Pharmaceuticals Announces Positive Phase 1 Clinical Study of EDP-305, its Lead FXR Agonist for the Treatment of Non-alcoholic Steatohepatitis (NASH)

Enanta Pharmaceuticals Announces that AbbVie’s MAVIRET^® (glecaprevir/pibrentasvir) Received Approval in U.S., E.U. and Japan for the 8-Week Treatment Most Major Genotypes of Chronic Hepatitis C Infection

Enanta Pharmaceuticals Announces Positive Phase 1 Results and Initiation of Phase 2a Clinical Study of EDP-938 for Respiratory Syncytial Virus

Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in a Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus

Enanta Adds Hepatitis B Virus to its Pipeline with the Initiation of Phase 1 Clinical Study of Core Inhibitor EDP-514

Enanta Pharmaceuticals’ HCV Collaboration Partner AbbVie Receives Marketing Authorization from the European Commission to Shorten MAVIRET® (glecaprevir/pibrentasvir) to Eight Weeks for Treatment-Naïve Genotype 3 HCV Patients with Compensated Cirrhosis

Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19

Enanta Pharmaceuticals Announces Positive Data from Phase 1 Study of EDP-514 in Nucleos(t)ide Reverse Transcriptase Inhibitor (NUC)-Suppressed Patients with Chronic Hepatitis B Virus Infection

Enanta Pharmaceuticals Announces Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus Core Inhibitor, in Viremic Chronic HBV Patients

Enanta Pharmaceuticals Adds COVID-19 to its Pipeline with the Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19